ValueScreener

ValueScreener company report

SAB Biotherapeutics, Inc. (SABS)

NASDAQ / Healthcare / Biotechnology

Share price

2.59 USD Market dataClose of Oct 15, 2026

Market capitalisation

235.7M USD Market dataClose of Oct 15, 2026
Market data
Oct 15, 2026
Filed accounts
FY2025, filed Mar 9, 2026
Ratios computed
Oct 15, 2026
Filed years
6, FY2020 to FY2025
Four kinds of sourceSEC filingCompany statementMarket dataComputedWhat each means
SEC filingFiled with the SEC
Read from a statement the company filed with the SEC, with the form, fiscal year, filing date and accession beside it.
Company statementCompany statement
What the company says about itself in a filing: an 8-K item, the auditor, its own segment names.
Market dataMarket data
Prices, market value and what analysts publish, with the date they are as of.
ComputedComputed by ValueScreener
Worked out by us from the other three, with the inputs and the formula one press away. A score is a research output, not a rating or a recommendation.
Reading

1 of 10

Overview

What the business is, what it costs, and how it reads on four questions.

Market dataSEC filingComputed

Four questions, at a glance

Quality

Return on equity

8.8% Computed

From the FY2025 filing

Read quality

Valuation

Price to book

1.56x Computed

FY2025 accounts, priced at the latest close

Read valuation

Cash generation

Free cash flow yield

-19.4% Computed

FY2025 accounts, priced at the latest close

Read cash generation

Revenue and net income, by fiscal year

FY2019 Revenue: 3.4M USDFY2019 Net income: -9.0M USDFY2020 Revenue: 55.2M USDFY2020 Net income: 20.1M USDFY2021 Revenue: 60.9M USDFY2021 Net income: -17.1M USDFY2022 Revenue: 23.9M USDFY2022 Net income: -18.7M USDFY2023 Revenue: 2.2M USDFY2023 Net income: -42.2M USDFY2024 Revenue: 1.3M USDFY2024 Net income: -34.1M USDFY2025 Revenue: 0.00 USDFY2025 Net income: 13.3M USD
Revenue Net income7 fiscal years; a year whose statement names no SEC filing is market data, and the table in Filings says which.
Named tests met
0 of 30 Which tests
The business, and the score behind its five axes

The reading, in brief

Is it cheap

Price to earnings is 11.77x at the close of 2026-10-15 on FY2025 figures; the lines are 15.00x (Graham's defensive ceiling) and, by market convention, 10.00x, 25.00x and 40.00x, and this sits between 10.00x and 15.00x.

Today, against the Biotechnology industry (53 companies), 11.77x sits at the 46th percentile; the middle half of that group runs from 4.71x to 41.19x.

Is it good

Return on equity was 8.8% in FY2025, in the band labelled "Ordinary" (8.0% to 15.0%), on lines anchored on Damodaran's cost-of-capital data.

Today, against the Biotechnology industry (494 companies), 8.8% sits at the 91st percentile; the middle half of that group runs from -146.9% to -28.9%.

Is it safe

Current ratio was 9.46 in FY2025, in the band labelled "At or above Graham's requirement" (2.00 and above), on lines anchored on Graham's defensive-investor criteria, suggesting short-term assets well above short-term obligations.

Today, against the Biotechnology industry (556 companies), 9.46 sits at the 76th percentile; the middle half of that group runs from 2.39 to 9.18.

Year by year against peers
Whether SAB Biotherapeutics, Inc.'s return on equity stayed above the median of the Biotechnology industry, year by year. (FY2021 to FY2025, 5 fiscal years of SAB Biotherapeutics, Inc. with a comparable figure)
The direction
Which way SAB Biotherapeutics, Inc.'s current ratio has moved, and how steadily. (FY2019 to FY2025, 7 filed years of SAB Biotherapeutics, Inc.)
What could explain it
What in SAB Biotherapeutics, Inc.'s filed statements could explain the movements. (4 readings drawn from the statement lines SAB Biotherapeutics, Inc. filed)
What to check next
What to check next on SAB Biotherapeutics, Inc., and where in its filings. (3 questions for SAB Biotherapeutics, Inc.)
In one paragraph
One paragraph on SAB Biotherapeutics, Inc.'s returns, cash, balance sheet and price. (6 of sixteen figures read for SAB Biotherapeutics, Inc.)

These are SABS’s filed figures. The research desk says what they mean, against peers and its own years, with what to check next.

Research SABSPart of Serious. New accounts start with 30 days of Professional, free, no card.

2 of 10

What changed

The newest filing, what it moved, and when the next one is due.

SEC filingCompany statement

The newest accounts on file are the FY2025 annual report: 10-K, filed Mar 9, 2026, accession 0001833214-26-000003.

3 of 10

Quality

The returns the business earns on its capital, and the margins behind them.

SEC filingComputed

SAB Biotherapeutics, Inc: returns on capital and margins, each with its source
FigureValue, source and document
Return on invested capital, after tax
Why n/a

The filed borrowings do not add up to a total we can stand behind: the filer's own liability subtotals leave room for debt we did not read.

n/a ComputedFY2025 10-K, filed Mar 9, 2026, 0001833214-26-000003
Return on equity8.8% ComputedFY2025 10-K, filed Mar 9, 2026, 0001833214-26-000003
Return on capital employed, pre-tax-30.2% ComputedFY2025 10-K, filed Mar 9, 2026, 0001833214-26-000003
Return on assets7.7% ComputedFY2025 10-K, filed Mar 9, 2026, 0001833214-26-000003
Gross margin
Why n/m

This company reported no revenue for the period, so every ratio measured against revenue is undefined. It is not a zero margin, it is the absence of a denominator. Cash runway is the measure that applies.

n/m ComputedFY2025 10-K, filed Mar 9, 2026, 0001833214-26-000003
Operating margin
Why n/m

This company reported no revenue for the period, so every ratio measured against revenue is undefined. It is not a zero margin, it is the absence of a denominator. Cash runway is the measure that applies.

n/m ComputedFY2025 10-K, filed Mar 9, 2026, 0001833214-26-000003
Net margin
Why n/m

This company reported no revenue for the period, so every ratio measured against revenue is undefined. It is not a zero margin, it is the absence of a denominator. Cash runway is the measure that applies.

n/m ComputedFY2025 10-K, filed Mar 9, 2026, 0001833214-26-000003

4 of 10

Financial strength

What it owes against what it owns, and whether it can meet what falls due.

SEC filingComputedCompany statement

SAB Biotherapeutics, Inc: leverage, liquidity and distress, each with its source
FigureValue, source and document
Debt to equity
Why n/a

The filed borrowings do not add up to a total we can stand behind: the filer's own liability subtotals leave room for debt we did not read.

n/a ComputedFY2025 10-K, filed Mar 9, 2026, 0001833214-26-000003
Current ratio9.46 ComputedFY2025 10-K, filed Mar 9, 2026, 0001833214-26-000003
Quick ratio9.46 ComputedFY2025 10-K, filed Mar 9, 2026, 0001833214-26-000003
Interest coverage
Why n/m

Operating income is zero or below, so there is no operating profit to cover the interest bill and coverage is not meaningful (n/m).

n/m ComputedFY2025 10-K, filed Mar 9, 2026, 0001833214-26-000003
Altman Z-score
Why n/m

This company reported no revenue for the period, so every ratio measured against revenue is undefined. It is not a zero margin, it is the absence of a denominator. Cash runway is the measure that applies.

n/m ComputedClose of Oct 15, 2026 · FY2025 10-K, filed Mar 9, 2026, 0001833214-26-000003
Net debt
Why n/a

The FY2025 balance sheet carries no net debt we could read.

n/a ComputedFY2025 10-K, filed Mar 9, 2026, 0001833214-26-000003
Total assets 172.8MTotal liabilities 21.3MShareholders' equity 151.5MOwnsOwes, and equity
Total assets Total liabilities Shareholders’ equity
The balance sheet, line by line

Financial health

What SAB Biotherapeutics, Inc owned and owed at the end of fiscal 2025, from the balance sheet it filed (10-K, filed Mar 9, 2026, 0001833214-26-000003).

SAB Biotherapeutics, Inc: balance sheet position
Total assets172.8M FiledFY2025 10-K, filed Mar 9, 2026
Total liabilities21.3M FiledFY2025 10-K, filed Mar 9, 2026
Shareholders' equity151.5M FiledFY2025 10-K, filed Mar 9, 2026
Cash96.6M FiledFY2025 10-K, filed Mar 9, 2026
Total debtn/a FiledFY2025 10-K, filed Mar 9, 2026
Net debtn/a
Current ratio9.46
Debt to equityn/a
  • Debt to equity: FY2025: The filed borrowings do not add up to a total we can stand behind: the filer's own liability subtotals leave room for debt we did not read.
  • Interest cover: FY2025: Operating income is zero or below, so there is no operating profit to cover the interest bill and coverage is not meaningful (n/m).

Read from the filed balance sheet for each year, with the income statement of the same year supplying operating profit where a ratio needs it. Nothing here is a view on whether this company is sound.

5 of 10

Valuation context

What the market charges for it, against its own record and companies like it.

Market dataSEC filingComputed

SAB Biotherapeutics, Inc: what the market charges, each with its source
FigureValue, source and document
Price to earnings
Why n/m

Earnings are zero or negative, so a price to earnings multiple is not meaningful. A negative P/E is not a cheap company and a large positive one from a near-zero denominator is not an expensive one.

n/m ComputedClose of Oct 15, 2026 · FY2025 10-K, filed Mar 9, 2026, 0001833214-26-000003
P/E on trailing twelve months12.30x ComputedClose of Oct 15, 2026 · Trailing four quarters, each as known on the day; the quarterly filings are listed under Filings
Price to book1.56x ComputedClose of Oct 15, 2026 · FY2025 10-K, filed Mar 9, 2026, 0001833214-26-000003
Price to sales
Why n/m

This company reported no revenue for the period, so every ratio measured against revenue is undefined. It is not a zero margin, it is the absence of a denominator. Cash runway is the measure that applies.

n/m ComputedClose of Oct 15, 2026 · FY2025 10-K, filed Mar 9, 2026, 0001833214-26-000003
Enterprise value to EBIT
Why n/a

We do not hold this figure for this company, so there is nothing to show.

n/a ComputedClose of Oct 15, 2026 · FY2025 10-K, filed Mar 9, 2026, 0001833214-26-000003
Enterprise value to EBITDA
Why n/m

EBITDA is zero or negative, so a multiple of it is not meaningful.

n/m ComputedClose of Oct 15, 2026 · FY2025 10-K, filed Mar 9, 2026, 0001833214-26-000003
Price to earnings over growth
Why n/m

Earnings are zero or negative, so a price to earnings multiple is not meaningful. A negative P/E is not a cheap company and a large positive one from a near-zero denominator is not an expensive one.

n/m ComputedClose of Oct 15, 2026 · FY2025 10-K, filed Mar 9, 2026, 0001833214-26-000003
Diluted earnings per share-0.79 USD FiledFY2025 10-K, filed Mar 9, 2026, 0001833214-26-000003
Graham number
Why n/m

Earnings are zero or negative, so a price to earnings multiple is not meaningful. A negative P/E is not a cheap company and a large positive one from a near-zero denominator is not an expensive one.

n/m ComputedFY2025 10-K, filed Mar 9, 2026, 0001833214-26-000003

We publish no fair value or price target of our own. Value SABS on your own assumptions in the DCF workbench, starting from the filed figures.

Its own record, and companies like it

Valuation

What the market charges for SAB Biotherapeutics, Inc today, and the multiples it has carried. No value of ours: the figures are the filings’ and the market’s.

SAB Biotherapeutics, Inc: valuation
Share price2.59 USD
Market capitalisation235.7M USD
Enterprise value to EBITDAn/m
Graham numbern/m
Diluted earnings per share, FY2025-0.79 USD

Price to earnings on trailing twelve months, a different basis from the fiscal-year P/E above, since Mar 29, 2022: low 12.30x, median 15.26x, high 17.09x, latest 12.30x. 47 trading days with a meaningful ratio, 1,092 more on a loss and left out. Each close over the trailing twelve months of earnings as known that day: a quarter counts from the day it was filed.

Companies like SAB Biotherapeutics, Inc

  1. Lexeo Therapeutics, Inc. Common Stock (LXEO)Market cap 226.6M USD
  2. Bicycle Therapeutics plc (BCYC)Market cap 252.0M USD
  3. BridgeBio Oncology Therapeutics Inc. (BBOT)Market cap 236.5M USD
  4. X4 Pharmaceuticals, Inc. (XFOR)Market cap 261.7M USD
  5. EyePoint Pharmaceuticals, Inc. (EYPT)Market cap 263.3M USD

Same industry (Biotechnology) and size band (Micro, 50M to 300M), nearest in market value and current ratio. Each of those counts equally, by how many of the companies considered sit between the two on it. Closest first: the order is likeness and nothing else.

6 of 10

Cash generation

Whether profit arrives as cash, and what is paid back to shareholders.

SEC filingComputed

SAB Biotherapeutics, Inc: cash generation and what is paid out, each with its source
FigureValue, source and document
Free cash flow yield-19.4% ComputedClose of Oct 15, 2026 · FY2025 10-K, filed Mar 9, 2026, 0001833214-26-000003
Free cash flow-45.7M USD ComputedFY2025 10-K, filed Mar 9, 2026, 0001833214-26-000003
Free cash flow margin
Why n/m

This company reported no revenue for the period, so every ratio measured against revenue is undefined. It is not a zero margin, it is the absence of a denominator. Cash runway is the measure that applies.

n/m ComputedFY2025 10-K, filed Mar 9, 2026, 0001833214-26-000003
Dividend yield
Why n/a

We do not hold this figure for this company, so there is nothing to show.

n/a ComputedClose of Oct 15, 2026 · FY2025 10-K, filed Mar 9, 2026, 0001833214-26-000003
Payout ratio
Why n/a

We do not hold this figure for this company, so there is nothing to show.

n/a ComputedFY2025 10-K, filed Mar 9, 2026, 0001833214-26-000003
FY2019 Free cash flow: -9.8M USDFY2019 Net income: -9.0M USDFY2020 Free cash flow: -2.7M USDFY2020 Net income: 20.1M USDFY2021 Free cash flow: -9.0M USDFY2021 Net income: -17.1M USDFY2022 Free cash flow: -25.6M USDFY2022 Net income: -18.7M USDFY2023 Free cash flow: -25.3M USDFY2023 Net income: -42.2M USDFY2024 Free cash flow: -34.6M USDFY2024 Net income: -34.1M USDFY2025 Free cash flow: -45.7M USDFY2025 Net income: 13.3M USD
Free cash flow Net incomeProfit that arrives as cash stands level with net income; a gap year after year is worth reading about.

7 of 10

Filings

Every figure, the year it is for and the document it was read from.

SEC filingMarket data

The filed figures

Computed from the accounts this company filed with the SEC and, in a ratio with a price in it, the last close, dated on this page. Every filed figure below carries the fiscal year and the filing date its accounts were read from, and every blank carries the reason it is blank. Nothing here is a view on this company.

SAB Biotherapeutics, Inc.: the eight ratios, with the fiscal year and filing date behind each.
FigureValueYearAs of
n/mFY2025Oct 15, 2026
n/m Not meaningful for this company, such as a P/E on negative earnings or a bank's EV/EBIT.
1.56xFY2025Oct 15, 2026
n/aFY2025Oct 15, 2026
n/a Operating profit is zero or negative, so there is no profit for a buyer's price to be a multiple of.
-19.4%FY2025Oct 15, 2026
n/aFY2025Mar 9, 2026
n/a The filed borrowings do not add up to a total we can stand behind: the filer's own liability subtotals leave room for debt we did not read.
n/aFY2025Oct 15, 2026
n/a The filed cash flow statement reports no dividend paid at all. That is not the same as a filed zero, and we will not read it as one.
n/aFY2025Mar 9, 2026
n/a The filed borrowings do not add up to a total we can stand behind: the filer's own liability subtotals leave room for debt we did not read.
9.46FY2025Mar 9, 2026
n/mFY2025Oct 15, 2026
n/m Not meaningful for this company, such as a P/E on negative earnings or a bank's EV/EBIT.
n/mFY2025Oct 15, 2026
n/m Not meaningful for this company, such as a P/E on negative earnings or a bank's EV/EBIT.
n/mFY2025Oct 15, 2026
n/m Not meaningful for this company, such as a P/E on negative earnings or a bank's EV/EBIT.
n/mFY2025Mar 9, 2026
n/m Not meaningful for this company, such as a P/E on negative earnings or a bank's EV/EBIT.
n/mFY2025Mar 9, 2026
n/m Not meaningful for this company, such as a P/E on negative earnings or a bank's EV/EBIT.

The figures are computed from the accounts for fiscal 2025, the newest full year on file. 6 filed fiscal years on record, FY2020 to FY2025, from SEC EDGAR. Prices as of Oct 15, 2026. Ratios recomputed Oct 15, 2026. Two facts, because a recompute is not a fresh quote.

The year and the filing date name the statement each figure’s accounts are read from, and they stand even where the figure itself could not be computed: the line beneath a blank says what that statement did not carry. A figure’s name opens its formula and the filings behind it; a statement that names no SEC filing has no filing date, and reads n/a.

Ten years of filed figures, year by year

Ten years of filed figures

7 fiscal years, FY2019 to FY2025. 6 read from the annual reports SAB Biotherapeutics, Inc filed with the SEC, each naming its filing; the rest from statements that name none, which are market data. Amounts in USD, as reported.

SAB Biotherapeutics, Inc: revenue, earnings, free cash flow and returns, by fiscal year, with the filing each year was read from
YearRevenueOperating incomeNet incomeEPS, dilutedFree cash flowOperating marginReturn on equityFiling
FY20250.00-49.0M13.3M-0.79-45.7Mn/m8.8%10-K, Mar 9, 20260001833214-26-000003
FY20241.3M-42.9M-34.1M-3.68-34.6M-3244.9%-131.3%10-K, Mar 31, 20250000950170-25-046994
FY20232.2M-38.1M-42.2M-7.64-25.3M-1700.6%-73.6%10-K, Mar 29, 20240000950170-24-038219
FY202223.9M-28.9M-18.7M-4.31-25.6M-121.0%-60.3%10-K, Apr 14, 20230001437749-23-010343
FY202160.9M-13.4M-17.1M-6.30-9.0M-22.0%-44.5%10-K, Mar 29, 20220000950170-22-004935
FY202055.2M20.6M20.1M7.40-2.7M37.2%51.6%10-K, Mar 29, 20220000950170-22-004935
FY20193.4M-8.7M-9.0Mn/a-9.8M-252.0%n/mMarket data, supplied Oct 15, 2026accession n/a
  • Revenue: Revenue was not positive in both 2019 and 2025, so a compound rate across the window is not defined. Both figures are in the table.
  • Earnings: Earnings was not positive in both 2019 and 2025, so a compound rate across the window is not defined. Both figures are in the table.
  • Earnings per share: Earnings per share was not positive in both 2020 and 2025, so a compound rate across the window is not defined. Both figures are in the table.
  • Free cash flow: Free cash flow was not positive in both 2019 and 2025, so a compound rate across the window is not defined. Both figures are in the table.

Every figure in this section is a line of a filed annual statement or a ratio of two of them. Nothing here is estimated or smoothed. Earnings per share filed before a share split are put on today's share count, and say so. Nothing here is a verdict on the company.

8 of 10

Risks and guardrails

The accounting screens, the published tests, and the lines you can set to be told.

ComputedCompany statement

SAB Biotherapeutics, Inc: accounting screens and published tests, each with its source
FigureValue, source and document
Beneish M-score
Why n/m

This company reported no revenue for the period, so every ratio measured against revenue is undefined. It is not a zero margin, it is the absence of a denominator. Cash runway is the measure that applies.

n/m ComputedFY2025 10-K, filed Mar 9, 2026, 0001833214-26-000003
Piotroski F-score
Why n/m

This company reported no revenue for the period, so every ratio measured against revenue is undefined. It is not a zero margin, it is the absence of a denominator. Cash runway is the measure that applies.

n/m ComputedFY2025 10-K, filed Mar 9, 2026, 0001833214-26-000003
Named tests met0 of 30 Computed
Beta0.93 ComputedClose of Oct 15, 2026

The named tests

Of 30 tests value investors published: 0 met, 18 not met, 12 we could not complete. Counts, never a score: a single figure would have to decide that meeting one investor’s criteria and meeting another’s are worth the same.

Which tests, by name(all 30)
Meets
None of the named tests.
Does not
Defensive investor (Benjamin Graham); Deep value; Large cap, low P/E; High F-score, low P/B (Joseph Piotroski); Low PEG, low debt (Peter Lynch); High returns and growth; High yield, low payout; Dividends and buybacks; Low beta, profitable; Near the 52-week low; High returns, low debt; Owner earnings yield; High return on tangibles; Book or below, low debt (Walter Schloss); Tangible book or below; Cash-flow yield and ROIC; Cheapest quarter on P/B (David Dreman); Low P/E, growth, yield (John Neff)
Not measured
Earnings yield and ROIC (Joel Greenblatt); Three forensic scores; Gross margin, turnover (Robert Novy-Marx); EV/EBITDA and coverage; ROIC at or above WACC; Z-score and coverage (Edward Altman); Two thirds of NCAV (Benjamin Graham); P/E times P/B (Benjamin Graham); Low P/S, rising earnings (James O'Shaughnessy); Cash-covered dividend; Clean books, high ROIC; Cheapest quarter on P/E (David Dreman). A test with a figure we could not read is incomplete, never met and never failed.
Figures we could not read(21)
  • Debt to Equity: The filed borrowings do not add up to a total we can stand behind: the filer's own liability subtotals leave room for debt we did not read.
  • Piotroski F-Score: This company reported no revenue for the period, so every ratio measured against revenue is undefined. It is not a zero margin, it is the absence of a denominator. Cash runway is the measure that applies.
  • P/E Ratio: Earnings are zero or negative, so a price to earnings multiple is not meaningful. A negative P/E is not a cheap company and a large positive one from a near-zero denominator is not an expensive one.
  • EV/EBIT: We do not hold this figure for this company, so there is nothing to show.
  • Return on Invested Capital: The filed borrowings do not add up to a total we can stand behind: the filer's own liability subtotals leave room for debt we did not read.
  • Altman Z-Score: This company reported no revenue for the period, so every ratio measured against revenue is undefined. It is not a zero margin, it is the absence of a denominator. Cash runway is the measure that applies.
  • Beneish M-Score: This company reported no revenue for the period, so every ratio measured against revenue is undefined. It is not a zero margin, it is the absence of a denominator. Cash runway is the measure that applies.
  • PEG Ratio: Earnings are zero or negative, so a price to earnings multiple is not meaningful. A negative P/E is not a cheap company and a large positive one from a near-zero denominator is not an expensive one.
  • Rev Growth 5Y: This company reported no revenue for the period, so every ratio measured against revenue is undefined. It is not a zero margin, it is the absence of a denominator. Cash runway is the measure that applies.
  • Gross Margin: This company reported no revenue for the period, so every ratio measured against revenue is undefined. It is not a zero margin, it is the absence of a denominator. Cash runway is the measure that applies.
  • Asset Turnover: This company reported no revenue for the period, so every ratio measured against revenue is undefined. It is not a zero margin, it is the absence of a denominator. Cash runway is the measure that applies.
  • EV/EBITDA: EBITDA is zero or negative, so a multiple of it is not meaningful.
  • Interest Coverage: Operating income is zero or below, so there is no operating profit to cover the interest bill and coverage is not meaningful (n/m).
  • Dividend Yield: We do not hold this figure for this company, so there is nothing to show.
  • Payout Ratio: We do not hold this figure for this company, so there is nothing to show.
  • ROIC-WACC Spread: We do not hold this figure for this company, so there is nothing to show.
  • Price To Ncav: The filed share count failed its unit check, so there is no market value we can show you the inputs of.
  • Price To Graham: Earnings are zero or negative, so a price to earnings multiple is not meaningful. A negative P/E is not a cheap company and a large positive one from a near-zero denominator is not an expensive one.
  • P/S Ratio: This company reported no revenue for the period, so every ratio measured against revenue is undefined. It is not a zero margin, it is the absence of a denominator. Cash runway is the measure that applies.
  • Dividend Coverage Ratio: We do not hold this figure for this company, so there is nothing to show.
  • Dividend Streak: We do not hold this figure for this company, so there is nothing to show.

9 of 10

Declared positions

Whether anybody here owns this company.

Positions declared by Javier Sanz Alvarez: no holding in any company shown here, as of October 3, 2026.

10 of 10

Next step

What to do with what you have read.

A thesis is your reason for owning it, in your words, with the figures that must stay true. Checking those figures every night against the newest filed accounts, and telling you once when one breaks, is what the subscription adds.

More on this company

What this cannot tell you

  • 21 figures could not be read on this company, among them Debt to Equity, Piotroski F-Score, P/E Ratio. Each blank in the table above names the rest, with its reason. 12 named tests come back incomplete because of them, which is neither met nor missed.
  • We hold 6 filed fiscal years rather than 10, so the run above is shorter than a full decade and is counted as what it is.

And the one that is true of all of it: This is what the numbers say today. It cannot tell you the day one of them stops being true. Nothing here can, because the reasons are not written down.

Running this once is arithmetic on public documents and you are welcome to it. Writing down why you own each company, in your own words and with the numbers that have to stay true for it to hold, and then having those numbers re-checked every night against the newest filed accounts, and against the latest close where a rule watches a price, is Professional, the plan a new account starts on for 30 days, one trial per person. It writes to you the day one breaks, and stays quiet when nothing does. The check runs every night at 23:30 UTC. A filing is picked up the night after it is published.

Monitor my portfolioHow this is computed

No card. 30 free days, and nothing is charged unless you choose a plan.

Analyze your own portfolio

ValueScreener · valuescreener.ai · Computed from accounts filed with the SEC by this company, read from EDGAR, and from dated closing prices. On this page a filed figure opens into its formula, its inputs and the statement, fiscal year and filing date it was read from, and a price into the day of its close. A figure that cannot show that trail says so.

A computation on accounts filed with the SEC, not a recommendation and not advice. Past filings do not indicate future results. Risk disclaimer.

Margin Notes

Once a week, what changed in the filings of US-listed companies, why it can matter to a thesis, and what deserves a closer review. Grounded in filings, not market noise.

Site map

Apps

  • Android app coming soon
  • iPhone app coming soon
ValueScreener

Discover companies, research each one to its filings, track what matters, and take your work into your own spreadsheet.

ValueScreener is a trading name of Oliva Real Estate Technologies LLC, a Delaware limited liability company. Legal notices: legal@valuescreener.ai. © 2026 Oliva Real Estate Technologies LLC. All rights reserved.

Risk disclaimer. This service is provided for research and education only. Nothing on it is investment advice, a recommendation, or an offer to buy or sell any security. Capital is at risk, and past performance does not indicate future results. Figures come from filed accounts and may be incomplete, delayed or later restated, so verify a number against the filing before you act on it.

With your permission, Google Analytics, Microsoft Clarity and HubSpot set cookies to measure how this site and the product are used, including recordings of sessions. Nothing is set unless you allow it. Privacy policy